FDMT Stock Price, 4D Molecular Therapeutics, . Quote, Chart

Market Summary

USD25.75+0.18

Market Closed

0.70%

FDMT Stock Price

View Fullscreen

FDMT RSI Chart

FDMT Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-12.51

Price/Sales (Trailing)

63.12

Price/Free Cashflow

-16.47

FDMT Price/Sales (Trailing)

FDMT Profitability

Return on Equity

-17.41%

Return on Assets

-16.6%

Free Cashflow Yield

-6.07%

FDMT Fundamentals

FDMT Revenue

Revenue (TTM)

20.7M

Rev. Growth (Yr)

3.9K%

Rev. Growth (Qtr)

8.3K%

FDMT Earnings

Earnings (TTM)

-104.6M

Earnings Growth (Yr)

-12.97%

Earnings Growth (Qtr)

-0.37%

Breaking Down FDMT Revenue

Last 7 days

-4.3%

Last 30 days

-2.8%

Last 90 days

-3.9%

Trailing 12 Months

42.9%

How does FDMT drawdown profile look like?

FDMT Financial Health

Current Ratio

32.65

FDMT Investor Care

Shares Dilution (1Y)

53.92%

Diluted EPS (TTM)

-2.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.2M	2.3M	22.0M	20.7M
2022	17.3M	2.8M	2.0M	3.1M
2021	14.7M	15.8M	16.9M	18.0M
2020	8.6M	10.3M	12.0M	13.6M
2019	0	0	0	7.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 4D Molecular Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	bizily scott	sold	-45,045	25.74	-1,750	chief legal officer
Apr 16, 2024	bizily scott	acquired	13,295	7.59714	1,750	chief legal officer
Apr 01, 2024	bizily scott	acquired	102,224	12.5383	8,153	chief legal officer
Apr 01, 2024	bizily scott	sold	-259,102	31.78	-8,153	chief legal officer
Mar 27, 2024	bizily scott	acquired	151,541	25.98	5,833	chief legal officer
Mar 27, 2024	bizily scott	sold	-204,410	35.0438	-5,833	chief legal officer
Mar 18, 2024	bizily scott	sold	-54,722	31.27	-1,750	chief legal officer
Mar 18, 2024	bizily scott	acquired	13,295	7.59714	1,750	chief legal officer
Feb 27, 2024	bizily scott	sold	-57,270	30.00	-1,909	chief legal officer
Feb 27, 2024	bizily scott	acquired	38,638	20.24	1,909	chief legal officer

Which funds bought or sold FDMT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	JPMORGAN CHASE & CO	reduced	-6.03	4,145,780	12,825,000	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	23,226	23,226	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	16.87	208,361	457,032	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-12.5	244	892	-%
May 10, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-74,780	-	-%
May 10, 2024	CITIGROUP INC	added	271	4,046,730	4,883,630	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	7.79	9,782,740	23,862,900	0.01%
May 10, 2024	OSAIC HOLDINGS, INC.	sold off	-100	-31,910	-	-%
May 10, 2024	VANGUARD GROUP INC	added	25.34	36,728,200	74,550,600	-%
May 10, 2024	Covestor Ltd	new	-	-	-	-%

Are Funds Buying or Selling FDMT?

Are funds buying FDMT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FDMT

No. of Funds

Unveiling 4D Molecular Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	kirn david	4.7%	2,033,069	SC 13G/A
Feb 14, 2024	deep track capital, lp	5.34%	2,284,372	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	8.9%	4,400,000	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	5.0%	2,132,411	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.7%	4,163,211	SC 13G/A
Feb 13, 2024	janus henderson group plc	7.2%	3,093,296	SC 13G/A
Jan 25, 2024	blackrock inc.	8.1%	3,464,587	SC 13G/A
Jan 08, 2024	viking global investors lp	9.9%	4,247,914	SC 13G/A
Jan 08, 2024	viking global investors lp	11.2%	4,787,914	SC 13G/A
Jun 05, 2023	ra capital management, l.p.	6.7%	2,789,721	SC 13G

Recent SEC filings of 4D Molecular Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 18, 2024	4	Insider Trading
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 29, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to 4D Molecular Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

4D Molecular Therapeutics, Inc. News

Latest updates

4D Molecular Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-	-	-	20.00	0.00	0.00	1.00	1.00	0.00	1.00	0.00	1.00	15.00	2.00	5.00	7.00	4.00	4.00	-
Operating Expenses	4.2%	38.00	37.00	34.00	32.00	30.00	30.00	27.00	29.00	28.00	25.00	24.00	22.00	18.00	19.00	15.00	19.00	17.00	-
S&GA Expenses	-100.0%	-	11.00	9.00	9.00	8.00	8.00	8.00	8.00	8.00	7.00	8.00	7.00	6.00	7.00	4.00	3.00	4.00	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	16.00	15.00	13.00	-	12.00	16.00	13.00	-
Net Income	-0.4%	-32.40	-32.28	-10.26	-29.62	-28.68	-27.38	-25.69	-28.09	-26.34	-25.08	-22.24	-7.59	-16.41	-20.55	-7.83	-15.15	-13.16	-
Net Income Margin	-3.7%	-5.05*	-4.87*	-4.36*	-48.73*	-49.76*	-34.36*	-53.32*	-35.84*	-4.71*	-3.95*	-3.94*	-3.31*	-4.07*	-	-	-	-	-
Free Cashflow	-18.3%	-29.80	-25.20	-1.58	-22.87	-28.92	-23.31	-22.98	-21.97	-29.96	-26.93	-18.36	-16.94	-16.01	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	85.3%	630	340	362	353	244	262	280	303	325	353	241	255	270	288	58.00
Current Assets	80.6%	536	297	328	318	207	221	232	247	243	256	166	249	265	283	53.00
Cash Equivalents	10.6%	276	249	276	236	79.00	52.00	108	113	76.00	153	91.00	244	260	277	50.00
Net PPE	-3.3%	19.00	20.00	21.00	21.00	22.00	22.00	22.00	21.00	18.00	14.00	9.00	6.00	5.00	5.00	5.00
Liabilities	-8.5%	29.00	32.00	32.00	27.00	25.00	31.00	29.00	30.00	29.00	34.00	16.00	14.00	28.00	32.00	28.00
Current Liabilities	-13.4%	16.00	19.00	18.00	14.00	11.00	16.00	14.00	14.00	12.00	16.00	11.00	10.00	14.00	17.00	13.00
Shareholder's Equity	95.1%	601	308	330	325	219	231	251	273	296	319	224	241	242	256	-
Retained Earnings	-7.8%	-447	-415	-383	-372	-343	-314	-287	-261	-233	-207	-181	-159	-152	-135	-79.03
Additional Paid-In Capital	45.0%	1,048	723	712	698	562	547	540	536	531	527	406	400	395	392	6.00
Shares Outstanding	18.8%	51.00	43.00	43.00	42.00	33.00	33.00	32.00	32.00	32.00	32.00	27.00	27.00	27.00	-	-
Float	-	-	-	-	630	-	-	-	147	-	-	-	445	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-18.0%	-29,088	-24,650	-1,171	-22,065	-27,906	-22,214	-21,017	-19,904	-23,550	-21,836	-15,721	-16,205	-15,372	-17,499	-13,371	-6,169	-13,870	-
Share Based Compensation	1.0%	5,974	5,913	4,562	4,969	4,221	4,346	4,520	4,322	3,933	3,731	3,923	3,816	2,329	1,717	1,147	1,037	1,083	-
Cashflow From Investing	-3839.8%	-263,258	-6,682	29,981	49,288	43,130	-35,779	15,371	57,468	-54,110	-32,291	-139,010	-737	-642	-508	349	-120	-721	-
Cashflow From Financing	6595.3%	318,832	4,762	10,557	130,519	10,994	2,046	460	-50.00	629	116,139	1,977	820	-847	205,978	900	72,494	-389	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FDMT Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Collaboration and license revenue	$ 28	$ 298
Operating expenses:
Research and development	27,870	22,412
General and administrative	10,294	7,992
Total operating expenses	38,164	30,404
Loss from operations	(38,136)	(30,106)
Other income (expense):
Interest income	5,745	1,443
Other expense, net	(10)	(19)
Total other income, net	5,735	1,424
Net loss	$ (32,401)	$ (28,682)
Net loss per share, basic	$ (0.66)	$ (0.88)
Net loss per share, diluted	$ (0.66)	$ (0.88)
Weighted-average shares outstanding used in computing net loss per share, basic	49,271,984	32,723,530
Weighted-average shares outstanding used in computing net loss per share, diluted	49,271,984	32,723,530

FDMT Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 275,594	$ 249,108
Marketable securities	250,317	39,124
Prepaid expenses and other current assets	9,678	8,356
Total current assets	535,589	296,588
Marketable securities, long-term	62,942	10,954
Property and equipment, net	19,464	20,126
Operating lease right-of-use assets, net	11,118	11,539
Other assets	771	684
Total assets	629,884	339,891
Current liabilities
Accounts payable	4,217	3,515
Accrued and other current liabilities	9,013	12,014
Deferred revenue	0	273
Operating lease liabilities, current portion	3,173	3,149
Total current liabilities	16,403	18,951
Deferred revenue, net of current portion	1,322	972
Derivative liability	369	369
Operating lease liabilities, long-term portion	10,998	11,522
Other liabilities	231	248
Total liabilities	29,323	32,062
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 51,157,388 and 43,075,218 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	4
Additional paid-in-capital	1,048,393	723,136
Accumulated other comprehensive gain (loss)	(109)	16
Accumulated deficit	(447,728)	(415,327)
Total stockholders’ equity	600,561	307,829
Total liabilities and stockholders’ equity	$ 629,884	$ 339,891

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

CEO	Dr. David H. Kirn M.D.
WEBSITE	4dmoleculartherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	137

4D Molecular Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for 4D Molecular Therapeutics, Inc.? What does FDMT stand for in stocks?

FDMT is the stock ticker symbol of 4D Molecular Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 4D Molecular Therapeutics, Inc. (FDMT)?

As of Mon May 13 2024, market cap of 4D Molecular Therapeutics, Inc. is 1.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FDMT stock?

You can check FDMT's fair value in chart for subscribers.

What is the fair value of FDMT stock?

You can check FDMT's fair value in chart for subscribers. The fair value of 4D Molecular Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 4D Molecular Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FDMT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 4D Molecular Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether FDMT is over valued or under valued. Whether 4D Molecular Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact 4D Molecular Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FDMT.

What is 4D Molecular Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, FDMT's PE ratio (Price to Earnings) is -12.51 and Price to Sales (PS) ratio is 63.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FDMT PE ratio will change depending on the future growth rate expectations of investors.